KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank69
3Y CAGR-11.5%
5Y CAGR+6.1%
Year-over-Year Change
Research and development spending
3Y CAGR
-11.5%/yr
vs +23.0%/yr prior
5Y CAGR
+6.1%/yr
Recent deceleration
Acceleration
-34.5pp
Decelerating
Percentile
P69
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $55.64M | -22.4% |
| 2025 | $71.71M | -16.8% |
| 2024 | $86.17M | +7.3% |
| 2023 | $80.28M | +14.4% |
| 2022 | $70.17M | +70.0% |
| 2021 | $41.29M | +2.7% |
| 2020 | $40.19M | +14.8% |
| 2019 | $35.02M | +92.0% |
| 2018 | $18.24M | +44.0% |
| 2017 | $12.67M | - |